BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 3516950)

  • 1. Prognostic factors in non-Hodgkin's lymphoma.
    Tubiana M; Carde P; Burgers JM; Cosset JM; Van Glabbeke M; Somers R
    Int J Radiat Oncol Biol Phys; 1986 Apr; 12(4):503-14. PubMed ID: 3516950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined radiotherapy-chemotherapy for early stages non-Hodgkin's lymphoma: the 1975-1980 EORTC controlled lymphoma trial.
    Carde P; Burgers JM; van Glabbeke M; Hayat M; Cosset JM; Somers R; Sizoo W; Qasim MM; Lefur R; Abbatucci JS
    Radiother Oncol; 1984 Dec; 2(4):301-12. PubMed ID: 6395212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternating chemotherapy and radiotherapy for limited-stage intermediate and high-grade non-Hodgkin's lymphomas: long-term results for 96 patients with tumors > 5 cm.
    Munck JN; Dhermain F; Koscielny S; Girinsky T; Carde P; Bosq J; Decaudin D; JuliƩron M; Cosset JM; Hayat M
    Ann Oncol; 1996 Nov; 7(9):925-31. PubMed ID: 9006743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Adjuvant chemotherapy for localized non-Hodgkin's lymphoma with CVP therapy].
    Horikoshi N; Inagaki J; Ogawa M
    Gan To Kagaku Ryoho; 1983 Aug; 10(8):1878-84. PubMed ID: 6683953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localized extranodal lymphoma of the head and neck: retrospective analysis of a series of 107 patients from a single institution.
    Frata P; Buglione M; Grisanti S; Bonetti B; Vitali E; De Stefani A; Magri E; Peveri A; Marini G; Rossi G; Magrini SM
    Tumori; 2005; 91(6):456-62. PubMed ID: 16457141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An alternating chemotherapy and radiotherapy combination for non-Hodgkin's lymphomas of unfavourable histologies: feasibility and preliminary results.
    Cosset JM; Ozanne F; Henry-Amar M; Carde P; Amiel JL; Hayat M; Habrand JL; Tubiana M
    Radiother Oncol; 1985 Feb; 3(2):133-8. PubMed ID: 3838590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy.
    Jones SE; Miller TP; Connors JM
    J Clin Oncol; 1989 Sep; 7(9):1186-91. PubMed ID: 2671279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of localized non-Hodgkin's lymphoma: the experience at St. Bartholomew's Hospital 1972-1985.
    Richards MA; Gregory WM; Hall PA; Dhaliwal HS; Fernandez J; Stansfeld AG; Jones AE; Lister TA
    Hematol Oncol; 1989; 7(1):1-18. PubMed ID: 2909456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemotherapy with cyclophosphamide, vincristine, prednisone and the contribution of adriamycin in the treatment of adult non-Hodgkin's lymphomas a report of 131 cases.
    Parlier Y; Gorin NC; Najman A; Stachowiak J; Duhamel G
    Cancer; 1982 Aug; 50(3):401-9. PubMed ID: 7046899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
    Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
    Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined modality treatment for stage I-II non-Hodgkin's lymphomas: CVP versus BACOP chemotherapy.
    Bajetta E; Valagussa P; Bonadonna G; Lattuada A; Buzzoni R; Rilke F; Banfi A
    Int J Radiat Oncol Biol Phys; 1988 Jul; 15(1):3-12. PubMed ID: 2455701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffuse aggressive lymphoma.
    Fisher RI; Miller TP; O'Connor OA
    Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
    Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
    J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EORTC trial non-Hodgkin lymphomas.
    Somers R; Burgers JM; Qasim M; Van Glabbeke M; Duez N; Hayat M
    Eur J Cancer Clin Oncol; 1987 Mar; 23(3):283-93. PubMed ID: 3297719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
    Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF
    Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study.
    Yahalom J; Varsos G; Fuks Z; Myers J; Clarkson BD; Straus DJ
    Cancer; 1993 Apr; 71(7):2342-50. PubMed ID: 8453557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study.
    Kluin-Nelemans HC; Zagonel V; Anastasopoulou A; Bron D; Roozendaal KJ; Noordijk EM; Musson H; Teodorovic I; Maes B; Carbone A; Carde P; Thomas J
    J Natl Cancer Inst; 2001 Jan; 93(1):22-30. PubMed ID: 11136838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group.
    Meerwaldt JH; Carde P; Somers R; Thomas J; Kluin-Nelemans JC; Bron D; Noordijk EM; Cosset JM; Bijnens L; Teodorovic I; Hagenbeek A
    Ann Oncol; 1997; 8 Suppl 1():67-70. PubMed ID: 9187434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.